OncoMatch/Clinical Trials/NCT05491525
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Is NCT05491525 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2/3 trial studies Vibegron for neurogenic detrusor overactivity.
Treatment: Vibegron — The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: baclofen pump
Cannot have received: bladder augmentation surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Childrens Hospital · Little Rock, Arkansas
- Children's Hospital of Orange County · Orange, California
- Children's Hospital Colorado · Aurora, Colorado
- Nemours Childrens Health, Jacksonville · Jacksonville, Florida
- Wichita Urology Group · Wichita, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05491525 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior baclofen pump, bladder augmentation surgery disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify